Gut Bacteria Linked to High Blood Pressure and Depression
|
By LabMedica International staff writers Posted on 17 Sep 2019 |

Image: This infographic illustrates the connection between the brain, central nervous system and other organs and how they interact with a person\'s gut microbes to show different patterns from people with high blood pressure plus depression; high blood pressure without depression; depression with healthy blood pressure; or healthy subjects without depression or high blood pressure (Photo courtesy of Professor Bruce R. Stevens, PhD).
The microbiome is the genetic material of all the microbes, bacteria, fungi, protozoa and viruses that live on and inside the human body. The number of genes in all the microbes in one person's microbiome is 200 times the number of genes in the human genome.
A study of human gut bacteria, known as the gut microbiome, suggests that high blood pressure with depression may be a completely different disease than high blood pressure without depression. The gut may be targeted someday to prevent, diagnose and selectively treat different forms of high blood pressure with or without depression.
Scientists from the University of Florida College of Medicine (Gainesville, FL, USA) made a study of bacteria in the gut identified differences between people with high blood pressure compared to those with high blood pressure plus depression. They isolated DNA (deoxyribonucleic acid, the carrier of genetic information) from gut bacteria obtained from the stool samples of 105 volunteers. They used a new technique involving artificial-intelligence software to analyze the bacteria, which revealed four distinct types of bacterial genes and signature molecules.
Surprisingly, the investigators discovered unique patterns of bacteria from people with 1) high blood pressure plus depression; 2) high blood pressure without depression; 3) depression with healthy blood pressure; or 4) healthy subjects without depression or high blood pressure. The authors concluded that the results suggest different medical mechanisms of high blood pressure that correlate with signature molecules produced by gut bacteria. These molecules are thought to impact the cardiovascular system, metabolism, hormones and the nervous system.
Bruce R. Stevens, PhD, a Professor of Physiology & Functional Genomics, Medicine and Psychiatry and the lead author of the study, said, “People are 'meta-organisms' made up of roughly equal numbers of human cells and bacteria. Gut bacteria ecology interacts with our bodily physiology and brains, which may steer some people towards developing high blood pressure and depression. We believe we have uncovered new forms of high blood pressure: 'Depressive Hypertension' (high blood pressure with depression), which may be a completely different disease than 'Non-Depressive Hypertension' (high blood pressure without depression), which are each different from 'Non-Hypertensive Depression.” The study was presented at the American Heart Association's Hypertension 2019 Scientific Sessions on September 5, 2019, in New Orleans, LA, USA.
Related Links:
University of Florida College of Medicine
A study of human gut bacteria, known as the gut microbiome, suggests that high blood pressure with depression may be a completely different disease than high blood pressure without depression. The gut may be targeted someday to prevent, diagnose and selectively treat different forms of high blood pressure with or without depression.
Scientists from the University of Florida College of Medicine (Gainesville, FL, USA) made a study of bacteria in the gut identified differences between people with high blood pressure compared to those with high blood pressure plus depression. They isolated DNA (deoxyribonucleic acid, the carrier of genetic information) from gut bacteria obtained from the stool samples of 105 volunteers. They used a new technique involving artificial-intelligence software to analyze the bacteria, which revealed four distinct types of bacterial genes and signature molecules.
Surprisingly, the investigators discovered unique patterns of bacteria from people with 1) high blood pressure plus depression; 2) high blood pressure without depression; 3) depression with healthy blood pressure; or 4) healthy subjects without depression or high blood pressure. The authors concluded that the results suggest different medical mechanisms of high blood pressure that correlate with signature molecules produced by gut bacteria. These molecules are thought to impact the cardiovascular system, metabolism, hormones and the nervous system.
Bruce R. Stevens, PhD, a Professor of Physiology & Functional Genomics, Medicine and Psychiatry and the lead author of the study, said, “People are 'meta-organisms' made up of roughly equal numbers of human cells and bacteria. Gut bacteria ecology interacts with our bodily physiology and brains, which may steer some people towards developing high blood pressure and depression. We believe we have uncovered new forms of high blood pressure: 'Depressive Hypertension' (high blood pressure with depression), which may be a completely different disease than 'Non-Depressive Hypertension' (high blood pressure without depression), which are each different from 'Non-Hypertensive Depression.” The study was presented at the American Heart Association's Hypertension 2019 Scientific Sessions on September 5, 2019, in New Orleans, LA, USA.
Related Links:
University of Florida College of Medicine
Latest Pathology News
- AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
- Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
- Study Highlights Biomarker Testing Delays in Lung Cancer Care
- Stain-Free Imaging Platform Matches Standard Cancer Pathology
- New Companion Diagnostic Expands Precision Medicine in Prostate Cancer
- Uncertainty-Aware AI Platform Supports Automated HER2 Assessment in Breast Cancer
- AI Tool Speeds Brain Tumor Classification from Routine Histology Slides
- IHC Companion Diagnostic Standardizes Mismatch Repair Testing for Cancer Immunotherapy
- AI Pathology Tool Predicts Meningioma Recurrence from Routine Slides
- 3D Spatial Multi-Omics Maps Intra-Tumor Diversity in Colorectal Cancer
- Blood-Based Method Tracks Gene Activity in the Living Brain
- FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
- AI-Powered Atlas Maps Immune Structures Linked to Cancer Outcomes
- AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy
- Rapid AI Tool Predicts Cancer Spatial Gene Expression from Pathology Images
- AI Pathology Test Receives FDA Breakthrough for Bladder Cancer Risk Stratification
Channels
Clinical Chemistry
view channel
Alzheimer’s Biomarkers Identify Faster Cognitive Decline in Adults Over 80
Diagnosing the cause of cognitive decline in adults over 80 is challenging because multiple comorbidities can blur early clinical presentations. As a result, memory complaints are often attributed to normal... Read more
ADLM Issues Laboratory Guidance for Gender-Diverse Patient Care
Laboratory medicine increasingly intersects with gender-affirming care, where hormone therapy and rigid health record fields can complicate the interpretation of routine tests. Without appropriate clinical... Read moreMolecular Diagnostics
view channel
Blood Test Using Circular RNA Biomarkers Predicts Alzheimer’s Progression
Alzheimer’s disease evaluation commonly relies on plasma phosphorylated tau 217, along with invasive cerebrospinal fluid (CSF) testing and expensive PET. Blood-based approaches that can stratify risk years... Read more
Interpretable AI Tool Improves Prediction of Immunotherapy Response
Immune checkpoint inhibitors are standard treatment options across many cancers, but only a subset of patients benefit, making patient selection difficult. Because predictive biomarkers remain limited,... Read moreHematology
view channel
Blood Test Helps Predict Short-Term Mortality After Severe Heart Attack
ST-elevation myocardial infarction (STEMI) is a severe heart attack caused by complete blockage of a coronary artery. Early risk stratification at hospital admission is challenging but essential for guiding... Read more
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read moreImmunology
view channel
Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms
Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more
Emergency Department Opt-Out Testing Program Identifies Undiagnosed HIV
Undiagnosed HIV continues to drive avoidable morbidity and transmission, with many people identified only after substantial immune damage has occurred. In England, about one in 20 people living with HIV... Read more
Immune Biomarkers Could Identify Risk of Chronic Critical Illness on ICU Admission
Severe traumatic injury can trigger immune and organ dysfunction that complicates recovery in the intensive care unit. A subset of patients develop chronic critical illness, defined as dependence on intensive... Read morePathology
view channel
AI Pathology Tool Predicts Immunotherapy Response in Rare Cancers
Immunotherapy has transformed care for select malignancies, yet predicting which patients with rare cancers are most likely to benefit remains challenging. Clinicians often have only limited biomarkers... Read more
Uncertainty-Aware AI Tool Improves Digital Pathology for Cancer Subtyping
Reliable histologic subtyping guides therapy selection in oncology, yet diagnostic workflows grow more complex as whole-slide imaging and artificial intelligence (AI) expand. A persistent obstacle to clinical... Read moreTechnology
view channel
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read more
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read moreIndustry
view channel
Eurobio Scientific Completes Acquisition of CareDx Lab Products Division
Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Blood-Based CRISPR Test for Tuberculosis Gains Regulatory Approval in Colombia
Colombia remains a high-priority setting for tuberculosis, with a growing need for diagnostics that complement existing testing strategies and improve access to earlier diagnosis. Solutions that function... Read more








